Bioequivalence Studies
Bioequivalence studies demonstrate that a generic drug delivers the same active ingredient to the bloodstream as the brand-name reference product.
## What Is Bioequivalence?
Two drug products are bioequivalent when they deliver the same active ingredient to the site of action at the same rate and to the same extent. Bioequivalence (BE) studies are the scientific foundation for generic drug approval. Rather than repeating full clinical trials, generic manufacturers demonstrate that their formulation produces plasma concentration profiles statistically indistinguishable from the reference (brand-name) product.
## Study Design
### Standard Crossover Design
The typical BE study uses a two-period, two-sequence, single-dose crossover design. Each healthy volunteer receives both the test product and the reference product in randomized order, separated by a washout period of at least five half-lives. The crossover design allows each participant to serve as their own control, reducing inter-subject variability.
### Parallel Design
Used when the drug has a very long half-life (making crossover impractical) or when the study population cannot safely receive two doses. Each participant receives only one product.
## Pharmacokinetic Parameters
Three parameters are compared:
- **AUC (Area Under the Curve)**: Measures total drug exposure. AUC0-t and AUC0-inf are both assessed.
- **Cmax (Maximum Concentration)**: Measures peak exposure and rate of absorption.
- **Tmax (Time to Maximum Concentration)**: Assessed descriptively but not part of the statistical acceptance criterion.
## Acceptance Criteria
The FDA requires that the 90% confidence interval for the geometric mean ratio (test/reference) of both AUC and Cmax falls entirely within 80.00-125.00%. This is not the same as allowing a 20% difference -- in practice, approved generics typically show mean differences of 3-5% from the reference.
## Highly Variable Drugs
Some drugs have inherent within-subject pharmacokinetic variability exceeding 30%. For these, the FDA permits a reference-scaled average bioequivalence approach where acceptance limits widen proportionally to the reference product's own variability, preventing scientifically meaningless failures.
## Narrow Therapeutic Index Drugs
For drugs like warfarin, cyclosporine, and levothyroxine, tighter BE limits (90.00-111.11%) may be required because small differences in exposure can lead to clinically significant differences in efficacy or toxicity.
## Key Takeaways
- Bioequivalence studies replace full clinical trials for generic drug approval
- The standard design is a crossover study in healthy volunteers
- AUC and Cmax confidence intervals must fall within 80-125% of the reference
- Approved generics typically differ by only 3-5% from brand-name products
- Narrow therapeutic index drugs require tighter acceptance limits